CVRx (CVRX) Projected to Post Quarterly Earnings on Monday

CVRx (NASDAQ:CVRX) will likely be announcing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $14.49 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last posted its earnings results on Thursday, February 12th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%.The company had revenue of $16.02 million during the quarter, compared to analysts’ expectations of $15.75 million. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Trading Down 6.7%

NASDAQ:CVRX opened at $6.83 on Friday. The company has a 50-day moving average price of $8.05 and a 200-day moving average price of $8.05. CVRx has a 12 month low of $4.30 and a 12 month high of $11.30. The company has a current ratio of 7.63, a quick ratio of 6.72 and a debt-to-equity ratio of 1.26. The stock has a market cap of $180.52 million, a price-to-earnings ratio of -3.33 and a beta of 0.90.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CVRX shares. Cantor Fitzgerald raised shares of CVRx to a “strong-buy” rating in a research report on Tuesday, February 17th. Weiss Ratings cut shares of CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price target on shares of CVRx in a research report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $11.50.

Insider Transactions at CVRx

In other CVRx news, Director Mudit K. Jain purchased 46,800 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was bought at an average cost of $6.36 per share, with a total value of $297,648.00. Following the transaction, the director directly owned 980,183 shares in the company, valued at approximately $6,233,963.88. The trade was a 5.01% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 13.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CVRX. FourWorld Capital Management LLC raised its holdings in CVRx by 24.1% in the fourth quarter. FourWorld Capital Management LLC now owns 180,000 shares of the company’s stock worth $1,278,000 after buying an additional 35,000 shares during the last quarter. UBS Group AG raised its holdings in CVRx by 71.7% in the third quarter. UBS Group AG now owns 151,323 shares of the company’s stock worth $1,221,000 after buying an additional 63,179 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in CVRx by 24.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 157,260 shares of the company’s stock worth $1,117,000 after buying an additional 31,200 shares during the last quarter. Bank of America Corp DE raised its holdings in CVRx by 7.6% in the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock worth $524,000 after buying an additional 6,312 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in CVRx by 8.9% in the third quarter. Bridgeway Capital Management LLC now owns 54,000 shares of the company’s stock worth $436,000 after buying an additional 4,400 shares during the last quarter. 75.27% of the stock is owned by hedge funds and other institutional investors.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.